Fondazione Italiana Linfomi Ets
- Address
- Piazza Filippo Turati 5
Sponsor Overview
Specializations
Follicular lymphoma and related indolent B-cell lymphomas
Clinical research in follicular lymphoma includes relapsed and refractory disease, early-stage presentations, and high-tumor-burden cases, with a strong focus on immunotherapy, anti-CD20 therapy, and maintenance treatment strategies.
- Follicular lymphoma
- Early stage follicular lymphoma
- Relapsed or refractory follicular lymphoma
- High tumor burden disease
Research activity also extends to treatment adaptation in older patients and approaches aimed at limiting exposure to conventional chemotherapy while preserving disease control.
Diffuse large B-cell lymphoma and aggressive B-cell disease
The sponsor supports studies in diffuse large B-cell lymphoma, including ABC-DLBCL, elderly patients with newly diagnosed disease, and frail populations unsuitable for standard regimens, with interest in chemo-free approaches and immunochemotherapy.
- Diffuse large B-cell lymphoma
- ABC-DLBCL
- Elderly patients with DLBCL
- Non-Hodgkin lymphoma
Its trial portfolio also includes interventions for aggressive B-cell lymphoma subtypes requiring treatment refinement in older or medically unfit patients.
Hodgkin lymphoma and transplant-adjacent salvage care
Research in Hodgkin lymphoma addresses patients who are unsuitable for standard chemotherapy as well as relapsed or refractory disease requiring salvage treatment and consideration of autologous stem-cell transplantation.
- Hodgkin lymphoma
- Hodgkin’s lymphoma
- Relapsed or refractory disease
- Transplant-eligible salvage settings
These studies reflect interest in checkpoint inhibition and other non-standard options for patients with limited tolerance to conventional therapy.
Mantle cell lymphoma and advanced targeted therapy
Clinical activity in mantle cell lymphoma spans untreated elderly patients, high-risk disease, relapsed or refractory settings, and post-CAR-T relapse, with emphasis on BTK inhibition, BCL-2 targeting, and bispecific antibodies.
- Mantle cell lymphoma
- Relapsed or refractory mantle cell lymphoma
- BTK inhibitor-treated disease
- Post CAR-T relapse
The portfolio also includes consolidation and frontline strategies for frail or high-risk patients with this lymphoma subtype.
T-cell lymphomas and rare plasma cell lymphoma
The sponsor funds research in T-cell lymphomas, including anaplastic large T-cell lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, alongside studies in plasmablastic lymphoma, a rare and aggressive lymphoid malignancy.
- Anaplastic large T-cell lymphoma
- Angioimmunoblastic T-cell lymphoma
- Peripheral T-cell lymphoma
- Plasmablastic lymphoma
These trials are centered on difficult-to-treat disease biology and the use of targeted agents and immunotherapy in uncommon lymphoma subtypes.
Sponsored Trials
Data & Insights
This sponsor works with 32 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 93 sites across their trial portfolio.
Therapeutic Focus
- 1.Hemic and Lymphatic Diseases15 trials249 other sponsors
Partnered Research Centres
93 centres- Address
- Contrada Amoretta, 83100 Avellino
- Address
- Piazzale Alessandro Ricchi 1, 09121 Cagliari
- Address
- Via Alcide De Gasperi, 184016 Pagani
- Address
- Via Fonte Romana 8, 65124 Pescara
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Fondazione Italiana Linfomi Ets.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.